Spots Global Cancer Trial Database for gastrinoma
Every month we try and update this database with for gastrinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors | NCT00602082 | Gastrointestina... Islet Cell Tumo... | capecitabine cisplatin streptozocin DNA analysis RNA analysis protein analysi... proteomic profi... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum | NCT00005860 | Cancer | floxuridine leucovorin calc... oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | NCT00416767 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | Federation Francophone de Cancerologie Digestive | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism | NCT00325104 | Hypercalcemia Familial Primar... | Parathyroid hor... Serum calcium t... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | NCT00227617 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... Neuroendocrine ... | bevacizumab 5-fluorouracil leucovorin oxaliplatin | 18 Years - | University of California, San Francisco | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00027638 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... | thalidomide | - | Memorial Sloan Kettering Cancer Center | |
| The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid | NCT00001191 | Gastrinoma Zollinger Ellis... | Pantoprazole Omeprazole | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | NCT02259725 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Somatostatinoma | regorafenib laboratory biom... | 18 Years - | University of Southern California | |
| Cinacalcet to Treat Familial Primary Hyperparathyroidism | NCT00325104 | Hypercalcemia Familial Primar... | Parathyroid hor... Serum calcium t... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00027638 | Gastrointestina... Islet Cell Tumo... Lung Cancer Neoplastic Synd... | thalidomide | - | Memorial Sloan Kettering Cancer Center | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | NCT02273752 | Estrogen Recept... Gastrinoma Glucagonoma HER2-negative B... Insulinoma Mucositis Oral Complicati... Pancreatic Poly... Progesterone Re... Recurrent Breas... Recurrent Islet... Recurrent Renal... Somatostatinoma Stage III Renal... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... Stage IV Renal ... | Everolimus | 18 Years - | Emory University | |
| Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00075439 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | gefitinib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00017199 | Gastrointestina... Islet Cell Tumo... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors | NCT00466856 | Head and Neck C... Islet Cell Tumo... Metastatic Canc... Pheochromocytom... | octreotide acet... yttrium Y 90 re... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | NCT02108782 | Gastrinoma Glucagonoma Insulinoma Pancreatic Poly... Recurrent Islet... Somatostatinoma | dovitinib lacta... pharmacological... laboratory biom... | 18 Years - | Academic and Community Cancer Research United | |
| Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors | NCT00131911 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Neuroendocrine ... Pancreatic Poly... Recurrent Gastr... Recurrent Islet... Somatostatinoma WDHA Syndrome | sorafenib tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| Evaluating Patients With Abnormal Levels of Gastric Acid | NCT00001240 | Achlorhydria Gastrinoma Zollinger Ellis... | - | National Institutes of Health Clinical Center (CC) | ||
| Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery | NCT00416767 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | fluorouracil irinotecan hydr... leucovorin calc... | 18 Years - 80 Years | Federation Francophone de Cancerologie Digestive | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | NCT00427349 | Gastrointestina... Islet Cell Tumo... Neoplastic Synd... | AMG 706 octreotide | 18 Years - | Eastern Cooperative Oncology Group | |
| PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors | NCT00017199 | Gastrointestina... Islet Cell Tumo... | bortezomib | 18 Years - | National Cancer Institute (NCI) | |
| Evaluating Patients With Abnormal Levels of Gastric Acid | NCT00001240 | Achlorhydria Gastrinoma Zollinger Ellis... | - | National Institutes of Health Clinical Center (CC) | ||
| EPO906 in Carcinoid and Other Neuroendocrine Tumors | NCT00050349 | Carcinoid Neuroendocrine ... | EPO906 epothilo... | 18 Years - | Novartis | |
| Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | NCT00227773 | Gastrointestina... Islet Cell Carc... | octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | NCT02259725 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Somatostatinoma | regorafenib laboratory biom... | 18 Years - | University of Southern California | |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer | NCT00006368 | Brain and Centr... Breast Cancer Gastrointestina... Islet Cell Tumo... Lung Cancer Lymphoma Melanoma (Skin) Neoplastic Synd... | yttrium Y 90-ed... | 18 Years - | Novartis | |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT00084461 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Regional Gastro... Somatostatinoma | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | NCT02031536 | Gastrinoma Glucagonoma Insulinoma Liver Metastase... Pancreatic Poly... Recurrent Islet... Somatostatinoma | everolimus placebo | 18 Years - | Eastern Cooperative Oncology Group | |
| Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas | NCT00001165 | Islet Cell Aden... Neoplasm Metast... Zollinger Ellis... | combined chemot... | - | National Institutes of Health Clinical Center (CC) | |
| Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | NCT00084461 | Gastrinoma Glucagonoma Insulinoma Metastatic Gast... Pancreatic Poly... Pulmonary Carci... Recurrent Gastr... Recurrent Islet... Regional Gastro... Somatostatinoma | romidepsin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | NCT01525082 | Gastrinoma Glucagonoma Insulinoma Pancreatic Poly... Recurrent Islet... Recurrent Pancr... Somatostatinoma Stage III Pancr... Stage IV Pancre... | Capecitabine Temozolomide Bevacizumab | 18 Years - | Stanford University | |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01824875 | Gastrinoma Glucagonoma Insulinoma Islet Cell Carc... Pancreatic Poly... Recurrent Islet... Somatostatinoma | temozolomide capecitabine | 18 Years - | Eastern Cooperative Oncology Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
